There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Axsome Therapeutics (AXSM – Research Report), Stoke Therapeutics (STOK – Research Report) and Cassava Sciences (SAVA – Research Report) with bullish sentiments.
Axsome Therapeutics (AXSM)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Axsome Therapeutics, with a price target of $180.00. The company’s shares closed last Monday at $71.09.
According to TipRanks.com, Selvaraju is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Axsome Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $110.00, which is a 44.8% upside from current levels. In a report released yesterday, Piper Sandler also upgraded the stock to Buy with a $90.00 price target.
See the top stocks recommended by analysts >>
Stoke Therapeutics (STOK)
In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Stoke Therapeutics, with a price target of $35.00. The company’s shares closed last Monday at $5.85, close to its 52-week low of $5.79.
According to TipRanks.com, Fein is a 1-star analyst with an average return of
Stoke Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $24.17, implying a 330.8% upside from current levels. In a report issued on July 27, Canaccord Genuity also maintained a Buy rating on the stock with a $18.00 price target.
Cassava Sciences (SAVA)
In a report released today, Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on Cassava Sciences, with a price target of $124.00. The company’s shares closed last Monday at $18.95, close to its 52-week low of $16.81.
According to TipRanks.com, Bernardino is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Cassava Sciences with a $99.50 average price target, representing a 391.1% upside. In a report issued on August 3, JonesTrading also maintained a Buy rating on the stock with a $75.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on AXSM:
- Axsome Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
- AXSM Upcoming Earnings Report: What to Expect?
- Mizuho biotech/biopharma analyst to hold analyst/industry conference call
- Axsome Therapeutics price target lowered to $190 from $200 at H.C. Wainwright
- Short Report: Bearishness on BioXcel at record high amid trial conduct review
